针对雄激素受体和信号转导与转录激活因子3治疗前列腺癌的新方法。
New approaches to target the androgen receptor and STAT3 for prostate cancer treatments.
作者信息
He Meilan, Young Charles Y F
机构信息
Department of Urology, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, USA.
出版信息
Mini Rev Med Chem. 2009 Mar;9(3):395-400. doi: 10.2174/1389557510909030395.
Prostate cancer (PCa) is a common cause of death in men and remains incurable in the androgen-refractory phase. Growing evidence has shown that the androgen receptor (AR) and signal transducers and activators of transcription 3 (STAT3) could be effective targets for androgen-refractory PCa therapy. Many strategies have been reported to inhibit the AR or STAT3 activities. In this review, we focus on the AR N-terminal domain and AR chaperones, as well as small molecule inhibitors to STAT3 with which we discuss some new approaches to target the AR and STAT3 as potential treatments for androgen-refractory PCa.
前列腺癌（PCa）是男性常见的死亡原因，在雄激素难治性阶段仍无法治愈。越来越多的证据表明，雄激素受体（AR）和信号转导及转录激活因子3（STAT3）可能是雄激素难治性前列腺癌治疗的有效靶点。据报道，有许多策略可抑制AR或STAT3的活性。在本综述中，我们重点关注AR的N端结构域和AR伴侣蛋白，以及针对STAT3的小分子抑制剂，我们将讨论一些针对AR和STAT3的新方法，作为雄激素难治性前列腺癌的潜在治疗手段。
Zotero 插件